DE19849465A1 - New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agents - Google Patents
New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agentsInfo
- Publication number
- DE19849465A1 DE19849465A1 DE1998149465 DE19849465A DE19849465A1 DE 19849465 A1 DE19849465 A1 DE 19849465A1 DE 1998149465 DE1998149465 DE 1998149465 DE 19849465 A DE19849465 A DE 19849465A DE 19849465 A1 DE19849465 A1 DE 19849465A1
- Authority
- DE
- Germany
- Prior art keywords
- tetraazacyclododecane
- aza
- dihydroxy
- bis
- heptanediyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052751 metal Inorganic materials 0.000 title claims description 31
- 239000002184 metal Substances 0.000 title claims description 31
- 239000003795 chemical substances by application Substances 0.000 title claims 3
- 238000001959 radiotherapy Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 title description 7
- 125000000129 anionic group Chemical group 0.000 title description 4
- 125000002091 cationic group Chemical group 0.000 title description 4
- 239000002872 contrast media Substances 0.000 title description 2
- -1 cationic metal complex Chemical class 0.000 claims abstract description 70
- 150000002500 ions Chemical class 0.000 claims abstract description 44
- 239000000539 dimer Substances 0.000 claims abstract description 16
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 10
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 21
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 21
- 150000004696 coordination complex Chemical class 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000008139 complexing agent Substances 0.000 claims description 11
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- WTNMWCJVEAIMLV-UHFFFAOYSA-N 2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WTNMWCJVEAIMLV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052797 bismuth Inorganic materials 0.000 claims description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 3
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 2
- JZNZSKXIEDHOBD-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OCC(O)C(CO)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 JZNZSKXIEDHOBD-UHFFFAOYSA-N 0.000 claims description 2
- BCFSXOVYBUXNCH-UHFFFAOYSA-N 2-[4-(3-amino-2-hydroxypropyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound NCC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 BCFSXOVYBUXNCH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 claims description 2
- 238000009206 nuclear medicine Methods 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 claims 2
- KHOMMWHGIAOVKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KHOMMWHGIAOVKF-UHFFFAOYSA-N 0.000 claims 1
- NXHUAYWRBFCZOA-UHFFFAOYSA-N 3-(1,4,7,10-tetrazacyclododec-1-yl)butane-1,2,4-triol Chemical compound OCC(O)C(CO)N1CCNCCNCCNCC1 NXHUAYWRBFCZOA-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 5
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052728 basic metal Inorganic materials 0.000 description 4
- 150000003818 basic metals Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 229910003440 dysprosium oxide Inorganic materials 0.000 description 2
- NLQFUUYNQFMIJW-UHFFFAOYSA-N dysprosium(iii) oxide Chemical compound O=[Dy]O[Dy]=O NLQFUUYNQFMIJW-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 150000002394 hexacarboxylic acid derivatives Chemical class 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- 125000006230 (methoxyethoxy)ethanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PIYNUZCGMLCXKJ-UHFFFAOYSA-N 1,4-dioxane-2,6-dione Chemical compound O=C1COCC(=O)O1 PIYNUZCGMLCXKJ-UHFFFAOYSA-N 0.000 description 1
- PGSBFNQOQHIMIK-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-(2-hydroxy-3-morpholin-4-ylpropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1CC(O)CN1CCOCC1 PGSBFNQOQHIMIK-UHFFFAOYSA-N 0.000 description 1
- PUBXWOKTNJWTKB-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[3-(dimethylamino)-2-hydroxypropyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound CN(C)CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 PUBXWOKTNJWTKB-UHFFFAOYSA-N 0.000 description 1
- ZNBFHFZIYYNDEK-UHFFFAOYSA-N 2-[6-[3-(carboxymethoxy)-2-hydroxypropyl]-4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C(=O)(O)COCC(CC1N(CCNCCN(CCN(C1)CC(=O)O)CC(=O)O)CC(=O)O)O ZNBFHFZIYYNDEK-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- MCFSNYMQISXQTF-UHFFFAOYSA-N 2-chlorosulfonylacetyl chloride Chemical compound ClC(=O)CS(Cl)(=O)=O MCFSNYMQISXQTF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical class OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- RWQXNROEHRGDNP-UHFFFAOYSA-N ethyl 3-[benzyl-(3-ethoxy-3-oxopropyl)amino]propanoate Chemical compound CCOC(=O)CCN(CCC(=O)OCC)CC1=CC=CC=C1 RWQXNROEHRGDNP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 1
- 229940075613 gadolinium oxide Drugs 0.000 description 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- ICXMVMOJRRHROE-UHFFFAOYSA-N n-benzyl-1-(oxiran-2-yl)-n-(oxiran-2-ylmethyl)methanamine Chemical compound C1OC1CN(CC=1C=CC=CC=1)CC1CO1 ICXMVMOJRRHROE-UHFFFAOYSA-N 0.000 description 1
- UYIXUPGBIXNDHN-UHFFFAOYSA-N neodymium(3+) Chemical compound [Nd+3] UYIXUPGBIXNDHN-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- WCWKKSOQLQEJTE-UHFFFAOYSA-N praseodymium(3+) Chemical compound [Pr+3] WCWKKSOQLQEJTE-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Die Erfindung betrifft neuartige dimere Ionenpaare, bestehend aus kationischen und anionischen Metallkomplexen, von denen mindestens ein Metallkomplex dimer sein muß, Verfahren zur Herstellung solcher Ionenpaare und deren Verwendung in der Diagnostik und Therapie.The invention relates to novel dimeric ion pairs consisting of cationic and anionic metal complexes, of which at least one metal complex may be dimer must, process for the preparation of such ion pairs and their use in the Diagnostics and therapy.
Schwermetallkomplexe (sogenannte Metallchelate) als Kontrastmittel sind in der Magnetresonanztomographie (MRT, MRI) Stand der Technik (EP 71564). In jüngster Zeit stellte sich heraus, daß derartige Komplexe prinzipiell auch für die Röntgen diagnostik einsetzbar sind (WO 96/16678). Die gute Verträglichkeit dieser Komplexe war besonders überraschend, da für die Röntgendiagnostik höhere Dosierungen als für die Magnetresonanztomographie nötig sind. Ein Nachteil vieler Zubereitungen von für die MRT entwickelten Metallkomplexen ist jedoch die erhöhte Viskosität von höher konzentrierten Lösungen.Heavy metal complexes (so-called metal chelates) as contrast agents are in the State of the art (EP 71564) magnetic resonance imaging (MRI, MRI). Most recently Time has turned out that such complexes can also be used for X-rays diagnostics can be used (WO 96/16678). The good tolerance of these complexes was particularly surprising, since higher doses than those for X-ray diagnostics are necessary for magnetic resonance imaging. A disadvantage of many preparations of metal complexes developed for MRI, however, is the increased viscosity of more concentrated solutions.
Es besteht daher Bedarf an neuen Metallkomplexverbindungen für die Röntgen diagnostik, die gut verträglich sind und bei höherer Konzentration eine geringere Viskosität und geringeren osmotischen Druck als die bekannten Zubereitungen aufweisen. There is therefore a need for new metal complex compounds for X-rays diagnostics that are well tolerated and less at higher concentrations Viscosity and lower osmotic pressure than the known preparations exhibit.
Diese Aufgabe wird durch den Gegenstand der vorliegenden Anmeldung gelöst, wie er in den Patentansprüchen genannt ist.This object is achieved by the subject matter of the present application, such as he is mentioned in the claims.
Es wurde nun gefunden, daß überraschenderweise dimere Ionenpaare gemäß der allgemeinen Formel I, bestehend aus mindestens einem schwermetallhaltigen Kation in Kombination mit mindestens einem schwermetallhaltigen Anion, von denen mindestens ein Ion ein dimerer Metallkomplex ist, hervorragend zur Lösung der gestellten Aufgabe geeignet sind.It has now been found that, surprisingly, dimeric ion pairs according to the general formula I, consisting of at least one heavy metal-containing cation in combination with at least one heavy metal anion, of which at least one ion is a dimeric metal complex, excellent for solving the task are suitable.
Gegenstand der Erfindung sind daher dimere Ionenpaare der allgemeinen Formel (I)
The invention therefore relates to dimeric ion pairs of the general formula (I)
Mk e|n Ma f|m (I)
Mk e | n Ma f | m (I)
worin
Mk für einen dimeren oder monomeren cyclischen kationischen
Metallkomplex steht,
Ma für einen dimeren oder monomeren cyclischen anionischen
Metallkomplex steht,
mit der Maßgabe, daß mindestens ein Metallkomplex Mk oder Ma dimer sein
muß,
e für die elektrische Ladung von Mk steht,
f für die elektrische Ladung von Ma steht,
n für die Anzahl der Ionen Mk steht und
m für die Anzahl der Ionen Ma steht.wherein
Mk represents a dimeric or monomeric cyclic cationic metal complex,
Ma represents a dimeric or monomeric cyclic anionic metal complex,
with the proviso that at least one metal complex must be Mk or Ma dimer,
e represents the electrical charge of Mk,
f represents the electrical charge of Ma,
n stands for the number of ions Mk and
m stands for the number of ions Ma.
Weiterhin sind Gegenstand der Erfindung dimere Ionenpaare der allgemeinen
Formel (I)
The invention furthermore relates to dimeric ion pairs of the general formula (I)
Mk e|n Ma f|m (I)
Mk e | n Ma f | m (I)
worin
Mk für einen dimeren oder monomeren cyclischen kationischen
Metallkomplex steht,
Ma für einen dimeren oder monomeren cyclischen anionischen
Metallkomplex steht,
mit den Maßgaben, daß mindestens ein Metallkomplex Mk oder Ma dimer sein
muß, und daß die Metallkomplexe Mk protonierte Gruppen und die
Metallkomplexe Ma deprotonierte Gruppen enthalten,
e für die elektrische Ladung von Mk steht,
f für die elektrische Ladung von Ma steht,
n für die Anzahl der Ionen Mk steht und
m für die Anzahl der Ionen Ma steht.wherein
Mk represents a dimeric or monomeric cyclic cationic metal complex,
Ma represents a dimeric or monomeric cyclic anionic metal complex,
with the provisos that at least one metal complex Mk or Ma must be dimeric and that the metal complexes Mk contain protonated groups and the metal complexes Ma deprotonate groups,
e represents the electrical charge of Mk,
f represents the electrical charge of Ma,
n stands for the number of ions Mk and
m stands for the number of ions Ma.
Die dimeren Metallkomplexe Mk und Ma bestehen aus zwei Metallionen und einem
dimeren Komplexbildner (Liganden) der Formel II, der in der Lage ist,
Chelatkomplexe zu bilden
The dimeric metal complexes Mk and Ma consist of two metal ions and a dimeric complexing agent (ligand) of the formula II, which is able to form chelate complexes
worin
L eine C2-C9-Alkylengruppe bedeutet, die gegebenenfalls durch 1-2
Sauerstoffatome und/oder 1-3 Stickstoffatome unterbrochen sein kann und/oder
mit 1-5 Hydroxygruppen und/oder gegebenenfalls mit 1-3 geradkettigen oder
verzweigten C1-C7-Acyl- und/oder C1-C7-Alkylgrupen, die jeweils gegebenenfalls
durch 1-3 Sauerstoffatome und/oder 1-2 Stickstoffatome unterbrochen sind
und/oder gegebenenfalls 1-5 Hydroxygruppen und/oder gegebenenfalls 1-2
Carboxy-, Phosphonat- oder Sulfonylreste enthalten, substituiert sein kann.wherein
L is a C 2 -C 9 alkylene group which can optionally be interrupted by 1-2 oxygen atoms and / or 1-3 nitrogen atoms and / or with 1-5 hydroxy groups and / or optionally with 1-3 straight-chain or branched C 1 - C 7 -acyl and / or C 1 -C 7 -alkyl groups, which are each optionally interrupted by 1-3 oxygen atoms and / or 1-2 nitrogen atoms and / or optionally 1-5 hydroxyl groups and / or optionally 1-2 carboxy- , Contain phosphonate or sulfonyl radicals, may be substituted.
Bevorzugt werden Linker L, die eine C2-C7-Alkylengruppe bedeuten und durch 1-2 Stickstoffatome unterbrochen sind. Linkers L which are a C 2 -C 7 -alkylene group and are interrupted by 1-2 nitrogen atoms are preferred.
Als Substituenten am Stickstoffatom des Linkers werden bevorzugt Wasserstoff, Alkylreste (z. B. Methyl, Ethyl), sowie substituierte Alkylreste wie z. B. Carboxymethyl, Carboxyethyl, -CH2-SO3H, -CH2-CH2-SO3H, 2,3-Dihydroxypropyl, CH(CH2OH)- CHOH-CH2OH, Hydroxyethyl CH2CH2OCH3, CH2CH2OCH2CH2OH, CH2CH2OCH2CH2OCH3 und Acylreste wie z. B. -CO-CH3, -CO-CH2-CH3, -CO-CH2-O-CH2COOH, -CO-CH2-OH, -CO-CH2-OCH3, COCH2OCH2CH2OCH3, CO-CHOH-COOH, CO-CHOH-CHOH-COOH, CO-CH2-SO3H.As substituents on the nitrogen atom of the linker are preferably hydrogen, alkyl radicals (z. B. Methyl, ethyl), and substituted alkyl groups such. B. carboxymethyl, carboxyethyl, -CH 2 -SO 3 H, -CH 2 -CH 2 -SO 3 H, 2,3-dihydroxypropyl, CH (CH 2 OH) - CHOH-CH 2 OH, hydroxyethyl CH 2 CH 2 OCH 3 , CH 2 CH 2 OCH 2 CH 2 OH, CH 2 CH 2 OCH 2 CH 2 OCH 3 and acyl radicals such as e.g. B. -CO-CH 3 , -CO-CH 2 -CH 3 , -CO-CH 2 -O-CH 2 COOH, -CO-CH 2 -OH, -CO-CH 2 -OCH 3 , COCH 2 OCH 2 CH 2 OCH 3 , CO-CHOH-COOH, CO-CHOH-CHOH-COOH, CO-CH 2 -SO 3 H.
Das Metallkomplexkation Mk enthält mindestens ein protoniertes Stickstoffatom.The metal complex cation Mk contains at least one protonated nitrogen atom.
Das Metallkomplexanion Ma enthält mindestens eine deprotonierte Gruppe wie z. B. eine Carboxylat-, Phosphonat- oder Sulfonat-Gruppe.The metal complex anion Ma contains at least one deprotonated group such as. B. a carboxylate, phosphonate or sulfonate group.
Als Linker seien beispielhaft die 1,7-Dihydroxy-4-aza-2,6-heptandiylgruppe, die 1,7- Dihydroxy-4-aza-N-(4-carboxy-3-oxa-1-oxo-butyl)-2,6-heptandiylgruppe, die 1,7- Dihydroxy-4-aza-N-(3-carboxy-1-oxo-propyl)-2,6-heptandiylgruppe, die 2,6- Dihydroxy-4-aza-N-methyl-1,7-heptandiylgruppe, die 2,6-Dihydroxy-4-aza-N-(2,3- dihydroxypropyl)-1,7-heptandiylgruppe, die 2,6-Dihydroxy-4-aza-N-(4-carboxy-2,3- dihydroxy-1-oxo-butyl)-1,7-heptandiylgruppe, die 2,6-Dihydroxy-4-aza-N-(4-carboxy- 3-oxa-1-oxo-butyl)-1,7-heptandiylgruppe, die 4-(2-Hydroxyethyl)-2,6-dihydroxy-4-aza-1,7-heptandiylgruppe und die 4- Sulfonylacetyl-2,6-dihydroxy-4-aza-1,7-heptandiylgruppe genannt. Examples of linkers are the 1,7-dihydroxy-4-aza-2,6-heptanediyl group, the 1,7- Dihydroxy-4-aza-N- (4-carboxy-3-oxa-1-oxo-butyl) -2,6-heptanediyl group, the 1,7- Dihydroxy-4-aza-N- (3-carboxy-1-oxo-propyl) -2,6-heptanediyl group, the 2,6- Dihydroxy-4-aza-N-methyl-1,7-heptanediyl group, the 2,6-dihydroxy-4-aza-N- (2,3- dihydroxypropyl) -1,7-heptanediyl group, the 2,6-dihydroxy-4-aza-N- (4-carboxy-2,3- dihydroxy-1-oxo-butyl) -1,7-heptanediyl group, the 2,6-dihydroxy-4-aza-N- (4-carboxy- 3-oxa-1-oxo-butyl) -1,7-heptanediyl group, the 4- (2-hydroxyethyl) -2,6-dihydroxy-4-aza-1,7-heptanediyl group and the 4- Called sulfonylacetyl-2,6-dihydroxy-4-aza-1,7-heptanediyl group.
Besonders bevorzugt werden die Verbindungen {1,1'-[1,7-Dihydroxy-4-aza-N-(4-carboxy-3-oxa-1-oxo-butyl)-2,6-heptandiyl]-bis- [(4,7,10-triscarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-Dysprosiumkomplex}- Salz des 1,1'-[1,7-Dihydroxy-4-aza-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)- 1,4,7,10-tetraazacyclododecan], Di-Dysprosiumkomplexes, {1,1'-[1,7-Dihydroxy-4- aza-N-(3-carboxy-1-oxo-propyl)-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)- 1,4,7,10-tetraazacyclododecan], Di-Dysprosiumkomplex}-Salz des 1,1'-[1,7- Dihydroxy-4-aza-N-methyl-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Dysprosiumkomplexes, {1,1'-[2,6-Dihydroxy-4-aza-N-(3- carboxy-1-oxo-propyl)-1,7-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Dysprosiumkomplex}-Salz des 1,1'-[2,6-Dihydroxy-4-aza- N-methyl-1,7-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Dysprosiumkomplexes, {1,1'-[4-(2-Hydroxyethyl)-2,6- dihydroxy-4-aza-1,7-heptandiyl]-bis-[(4,7,10-tricarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Gadoliniumkomplex}-{1,1'-[2,6-dihydroxy-4-aza-4- sulfoacetyl-1,7-heptandiyl]-bis-[(4,7,10-tricarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Gadoliniumkomplex}-Salz.The compounds are particularly preferred {1,1 '- [1,7-dihydroxy-4-aza-N- (4-carboxy-3-oxa-1-oxo-butyl) -2,6-heptanediyl] -bis- [(4,7,10-triscarboxymethyl) -1,4,7,10-tetraazacyclododecane], di-dysprosium complex} - Salt of 1,1 '- [1,7-dihydroxy-4-aza-2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) - 1,4,7,10-tetraazacyclododecane], di-dysprosium complex, {1,1 '- [1,7-dihydroxy-4- aza-N- (3-carboxy-1-oxo-propyl) -2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) - 1,4,7,10-tetraazacyclododecane], di-dysprosium complex} salt of 1,1 '- [1,7- Dihydroxy-4-aza-N-methyl-2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-dysprosium complex, {1,1 '- [2,6-dihydroxy-4-aza-N- (3- carboxy-1-oxo-propyl) -1,7-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-dysprosium complex} salt of 1,1 '- [2,6-dihydroxy-4-aza- N-methyl-1,7-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-dysprosium complex, {1,1 '- [4- (2-hydroxyethyl) -2,6- dihydroxy-4-aza-1,7-heptanediyl] -bis - [(4,7,10-tricarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-gadolinium complex} - {1,1 '- [2,6-dihydroxy-4-aza-4- sulfoacetyl-1,7-heptanediyl] -bis - [(4,7,10-tricarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-gadolinium complex} salt.
Verwendung finden die Metallionen mit den Ordnungszahlen 20-32, 39-51 oder 57- 83. Bevorzugt werden Metallionen mit den Ordnungszahlen 57-83 verwendet.The metal ions with atomic numbers 20-32, 39-51 or 57- are used 83. Metal ions with atomic numbers 57-83 are preferably used.
Als Komplexbildner können cyclische monomere oder dimere Polyaminosäuren verwendet werden (Fig. 1-3). Unter Polyaminosäuren sind sowohl Polyaminocarbonsäuren als auch Polyaminocarbonsäuren, die (eine) weitere Sulfonsäuregruppe(n) und/oder (eine) weitere Phosphonsäuregruppe(n) enthalten, zu verstehen.Cyclic monomeric or dimeric polyamino acids can be used as complexing agents ( FIGS. 1-3). Polyamino acids are understood to mean both polyaminocarboxylic acids and polyaminocarboxylic acids which contain (a) further sulfonic acid group (s) and / or (a) further phosphonic acid group (s).
Als monomere Komplexbildner kommen DOTA, DOXA, DO3A oder deren
substituierte Derivate, wie z. B.
10-(3-Amino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure,
10-(3-Morpholino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-
triessigsäure,
10-(2,3-Dihydroxy-1-hydroxymethylpropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-
triessigsäure (Butriol), 10-[3-N(-2,3-Dihydroxy-1-hydroxymethylpropyl)-amino-2-
hydroxypropyl]-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure, 10-(3-
Dimethylamino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure,
10-[3-N,N-bis(2-hydroxyethyl)amino-2-hydroxypropyl]-1,4,7,10-
tetraazacyclododecan-1,4,7-triessigsäure, 10-(3-Aza-4-carboxy-1-methyl-2-
oxobutyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure, 10-(2-Hydroxy-4-
carboxybutyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure, 10(5-carboxy-2-
hydroxy-4-oxa-pentyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure in Frage.As monomer complexing agents come DOTA, DOXA, DO3A or their substituted derivatives, such as. B.
10- (3-amino-2-hydroxypropyl) -1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10- (3-morpholino-2-hydroxypropyl) -1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid,
10- (2,3-Dihydroxy-1-hydroxymethylpropyl) -1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (butriol), 10- [3-N (-2,3-dihydroxy-1 -hydroxymethylpropyl) amino-2-hydroxypropyl] -1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10- (3-dimethylamino-2-hydroxypropyl) -1,4,7,10-tetraazacyclododecane -1,4,7-triacetic acid, 10- [3-N, N-bis (2-hydroxyethyl) amino-2-hydroxypropyl] -1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10 - (3-Aza-4-carboxy-1-methyl-2-oxobutyl) -1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10- (2-hydroxy-4-carboxybutyl) -1 , 4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10 (5-carboxy-2-hydroxy-4-oxapentyl) -1,4,7,10-tetraazacyclododecane-1,4,7- triacetic acid in question.
Bevorzugt werden monomere oder dimere DOTA-, DO3A und (DO3A)2L-Komplexe und deren substituierte Derivate und die Komplexbildner der Ansprüche 9 und 12.Monomeric or dimeric DOTA, DO3A and (DO3A) 2 L complexes and their substituted derivatives and the complexing agents of claims 9 and 12 are preferred.
Besonders bevorzugt sind die Komplexbildner der Ansprüche 9 und 12.The complexing agents of claims 9 and 12 are particularly preferred.
Als dimere cyclische Metallkomplexe werden Metallkomplexe mit durch ein Stickstoffatom unterbrochenem Linker besonders bevorzugt.As dimeric cyclic metal complexes are metal complexes with a Nitrogen atom interrupted linker is particularly preferred.
Das monomere Mk entsteht z. B. durch die Protonierung vom monomeren basischen Metallkomplex Mb, wobei für Mb beispielsweise [10-(3-Amino-2-hydroxypropyl)- 1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure, Dysprosiumkomplex], [10-(3- Amino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure, Gadoliniumkomplex], [10-(3-Amino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan- 1,4,7-triessigsäure, Bismuthkomplex], [10-(3-Morpholino-2-hydroxypropyl)-1,4,7,10- tetraazacyclododecan-1,4,7-triessigsäure, Ytterbiumkomplex] stehen kann.The monomeric Mk is formed e.g. B. by protonation of the monomeric basic Metal complex Mb, where for Mb [10- (3-amino-2-hydroxypropyl) - 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, dysprosium complex], [10- (3- Amino-2-hydroxypropyl) -1,4,7,10-tetraazacyclododecan-1,4,7-triacetic acid, Gadolinium complex], [10- (3-amino-2-hydroxypropyl) -1,4,7,10-tetraazacyclododecane 1,4,7-triacetic acid, bismuth complex], [10- (3-morpholino-2-hydroxypropyl) -1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid, ytterbium complex] can be.
Das dimere Mk entsteht z. B. durch Protonierung vom dimeren basischen Metallkomplex Mb, wobei für Mb beispielsweise {1,1'-[1,7-Dihydroxy-4-aza-2,6- heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10-tetraazacyclododecan, Di- Dysprosiumkomplex} stehen kann.The dimeric Mk arises e.g. B. by protonation of the dimeric basic Metal complex Mb, where for Mb for example {1,1 '- [1,7-dihydroxy-4-aza-2,6- heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10-tetraazacyclododecane, di- Dysprosium complex} can stand.
Das monomere Ma entsteht z. B. durch Deprotonierung vom monomeren aciden Metallkomplex Ms, wobei für Ms beispielsweise [Gd-DOTA], [Yb-DOTA], [Dy-DOTA], [Tb-DOTA], [Ho-DOTA], [Er-DOTA], [Mn-DOTA], (Cr-DOTA], [Fe-DOTA], [Co-DOTA], [Ni-DOTA], [Cu-DOTA], [Pr-DOTA], [Nd-DOTA], [Sm-DOTA], [Fe-DO3A], [Mn-DO3A], [Ni-DO3A], [Co-DO3A], [Cu-DO3A], [Fe-Butriol], [Mn-Butriol], [Ni-Butriol], [Co-Butriol], [Cu-Butriol], [Pb-Butriol], oder [Gd-10-(3-Aza-4-carboxy-1-methyl-2-oxobutyl)- 1,4,7,10-tetraazacyclododecan-1,4,7-triessigsäure] stehen kann. The monomeric Ma z. B. by deprotonation of the monomeric acid Metal complex Ms, where for Ms, for example, [Gd-DOTA], [Yb-DOTA], [Dy-DOTA], [Tb-DOTA], [Ho-DOTA], [Er-DOTA], [Mn-DOTA], (Cr-DOTA], [Fe-DOTA], [Co-DOTA], [Ni-DOTA], [Cu-DOTA], [Pr-DOTA], [Nd-DOTA], [Sm-DOTA], [Fe-DO3A], [Mn-DO3A], [Ni-DO3A], [Co-DO3A], [Cu-DO3A], [Fe-Butriol], [Mn-Butriol], [Ni-Butriol], [Co-Butriol], [Cu-butriol], [Pb-butriol], or [Gd-10- (3-aza-4-carboxy-1-methyl-2-oxobutyl) - 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid] can stand.
Das dimere Ma entsteht z. B. durch Deprotonierung vom dimeren aciden Metallkomplex Ms, wobei für Ms beispielsweise {1,1'-[1,7-Dihydroxy-4-aza-N-(4- carboxy-3-oxa-1-oxo-butyl)-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Dysprosiumkomplex}, {1,1'-[4-Carboxymethyl-1,7- dihydroxy-4-aza-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyi)-1,4,7,10- tetraazacyclododecan], Di-Gadoliniumkomplex} und {1,1'-[4-(2-Sulfonylethyl)-2,6- dihydroxy-4-aza-1,7-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10- tetraazacyclododecan], Di-Ytterbiumkomplex} stehen kann. Das Metallkomplexkation Mk kann Ladungen (e) von +1 bis +2 aufweisen. Günstige Eigenschaften weisen die Monokationen (e = +1) auf.The dimeric Ma z. B. by deprotonation of dimeric acid Metal complex Ms, where, for example, {1,1 '- [1,7-dihydroxy-4-aza-N- (4- carboxy-3-oxa-1-oxo-butyl) -2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-dysprosium complex}, {1,1 '- [4-carboxymethyl-1,7- dihydroxy-4-aza-2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyi) -1,4,7,10- tetraazacyclododecane], di-gadolinium complex} and {1,1 '- [4- (2-sulfonylethyl) -2,6- dihydroxy-4-aza-1,7-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10- tetraazacyclododecane], di-ytterbium complex}. The metal complex cation Mk can have charges (e) from +1 to +2. Favorable properties show the Monocations (e = +1).
Das Metallkomplexanion kann Ladungen (f) von (-1)-(-3) annehmen. Bevorzugt werden Ladungen von (-1). Die erfindungsgemäßen dimeren Ionenpaare der allgemeinen Formel I können eine unterschiedliche Anzahl von Kationen und Anionen aufweisen. So kann beispielsweise die Ladung eines Dianions durch zwei Monokationen kompensiert werden (n = 2, m = 1).The metal complex anion can take charges (f) from (-1) - (- 3). Prefers are charges of (-1). The dimeric ion pairs of the invention general formula I can have a different number of cations and Have anions. For example, a dianion can be charged by two Monocations can be compensated (n = 2, m = 1).
Die erfindungsgemäßen dimeren Ionenpaare müssen für die Anwendung elektrisch neutral sein. Im allgemeinen kompensieren sich die Ladungen von Mke und Maf gegenseitig ((n × e) + (m × f) = 0).The dimeric ion pairs according to the invention must be electrically neutral for use. In general, the charges of Mk e and Ma f compensate each other ((n × e) + (m × f) = 0).
Das Metallkomplexkation Mk und das Metallkomplexanion Ma können unterschiedliche Metalle enthalten.The metal complex cation Mk and the metal complex anion Ma can contain different metals.
Das Metallkomplexkation Mk und das Metallkomplexanion Ma können verschiedene Komplexbildner enthalten.The metal complex cation Mk and the metal complex anion Ma can be different Contain complexing agents.
Einer der beiden Metallkomplexe Mk oder Ma darf auch monomer vorliegen.One of the two metal complexes Mk or Ma may also be monomeric.
Die erfindungsgemäßen Verbindungen sind in jedem Fall für die Röntgendiagnostik geeignet.The compounds according to the invention are in any case for X-ray diagnosis suitable.
Sofern die erfindungsgemäßen Verbindungen paramagnetische Ionen enthalten, sind sie auch für die Magnetresonanztomographie geeignet. Es wurde gefunden, daß für diesen Zweck das Chrom(III)-, Eisen(II)-, Kobalt(II)-, Nickel(II)-, Kupfer(II)-, Praseodym(III)-, Neodym(III)-, Samarium(III)-, und das Ytterbium(III)-Ion geeignet sind. Besonders bevorzugt sind Komplexe der Ionen Gadolinium(III), Terbium(III), Dysprosium(III), Holmium(III), Erbium(III), Eisen(III) und Mangan(II). Mit radioaktiven Ionen sind die erfindungsgemäßen Verbindungen auch für die Nuklearmedizin (Diagnostik und Therapie) geeignet. Geeignet sind zum Beispiel die Radioisotope der Elemente Kupfer, Kobalt, Gallium, Germanium, Yttrium, Strontium, Technetium, Rhenium, Indium, Ytterbium, Gadolinium, Samarium, Silber, Gold, Rhenium, Bismut und Iridium. Bevorzugt sind die Radioisotope von Gallium, Indium und Technetium.If the compounds according to the invention contain paramagnetic ions, they are also suitable for magnetic resonance imaging. It was found, that for this purpose the chromium (III) -, iron (II) -, cobalt (II) -, nickel (II) -, copper (II) -, Praseodymium (III) -, Neodymium (III) -, Samarium (III) -, and the ytterbium (III) ion are suitable are. Complexes of the ions gadolinium (III), terbium (III), Dysprosium (III), holmium (III), erbium (III), iron (III) and manganese (II). With radioactive ions, the compounds according to the invention are also suitable for Nuclear medicine (diagnostics and therapy) suitable. For example, the Radioisotopes of the elements copper, cobalt, gallium, germanium, yttrium, strontium, Technetium, rhenium, indium, ytterbium, gadolinium, samarium, silver, gold, Rhenium, bismuth and iridium. The radioisotopes of gallium and indium are preferred and technetium.
Gegenstand der Erfindung ist daher auch die Verwendung der offenbarten Verbindungen zur Herstellung von Arzneimitteln für die o. g. medizinischen Anwendungen.The invention therefore also relates to the use of the disclosed Compounds for the manufacture of medicaments for the abovementioned medical Applications.
Die erfindungsgemäßen Verbindungen weisen überraschenderweise günstigere Eigenschaften auf - hinsichtlich Verträglichkeit, Viskosität, Osmolalität und/oder Löslichkeit - als aufgrund der entsprechenden Daten der Einzelkomponenten zu erwarten ist.The compounds according to the invention surprisingly have cheaper ones Properties on - with regard to compatibility, viscosity, osmolality and / or Solubility - as based on the corresponding data of the individual components is expected.
Geeignete Komplexbildner sind in EP 0 071 564, EP 0 405 704, EP 0 230 893,
US 4,880,008, US 4,899,755, US 5,250,285 und US 5,318,771 beschrieben.
Folgende Publikationen und die dort zitierte Literatur geben dem Fachmann
ergänzende Informationen über die benötigten Reaktionsbedingungen bei der
Herstellung der Metallkomplexe der erfindungsgemäßen Verbindungen:
Suitable complexing agents are described in EP 0 071 564, EP 0 405 704, EP 0 230 893, US 4,880,008, US 4,899,755, US 5,250,285 and US 5,318,771. The following publications and the literature cited therein provide the person skilled in the art with additional information about the reaction conditions required in the preparation of the metal complexes of the compounds according to the invention:
-
- Herstellung von Aminen, insbesondere Aminosäurederivaten:
Houben-Weyl, Band XI/1, Georg Thieme Verlag, Stuttgart, 1957
Houben-Weyl, Band XII/2, Georg Thieme Verlag, Stuttgart, 1958- Production of amines, especially amino acid derivatives:
Houben-Weyl, Volume XI / 1, Georg Thieme Verlag, Stuttgart, 1957
Houben-Weyl, Volume XII / 2, Georg Thieme Verlag, Stuttgart, 1958 -
- Herstellung von Alkylhalogeniden:
Houben-Weyl, Band V/3, Georg Thieme Verlag, Stuttgart, 1962
Houben-Weyl, Band V/4, Georg Thieme Verlag, Stuttgart, 1960- Production of alkyl halides:
Houben-Weyl, Volume V / 3, Georg Thieme Verlag, Stuttgart, 1962
Houben-Weyl, Volume V / 4, Georg Thieme Verlag, Stuttgart, 1960 -
- Herstellung von Carbonsäuren und Carbonsäurederivaten:
Houben-Weyl, Band VIII, Georg Thieme Verlag, Stuttgart, 1952- Production of carboxylic acids and carboxylic acid derivatives:
Houben-Weyl, Volume VIII, Georg Thieme Verlag, Stuttgart, 1952 -
- Reduktive Aminierung:
C.F. Lane, Synthesis 135 (1975) - Reductive amination:
CF Lane, Synthesis 135 (1975) -
- Herstellung von DTPA-Derivaten:
M.A. Williams, H. Rapoport, J. Org. Chem., 58, 1151 (1993)- Production of DTPA derivatives:
MA Williams, H. Rapoport, J. Org. Chem., 58, 1151 (1993)
Zur Herstellung der Ionenpaare gibt es zwei Möglichkeiten:There are two options for producing the ion pairs:
Die basischen Metallkomplexe Mb und die aciden Metallkomplexe Ms werden
getrennt hergestellt und anschließend in einem Lösungsmittel wie z. B. Wasser bei
einer Temperatur wie z. B. Raumtemperatur gemischt, gegebenenfalls gereinigt
und/oder im Vakuum zur Trockene eingeengt:
The basic metal complexes Mb and the acidic metal complexes Ms are prepared separately and then in a solvent such as. B. water at a temperature such. B. mixed room temperature, cleaned if necessary and / or concentrated to dryness in vacuo:
n Mb + m Ms → Mk e|n Ma f|m,
n Mb + m Ms → Mk e | n Ma f | m,
wobei
Mb für einen dimeren oder monomeren basischen Metallkomplex steht,
Ms für einen dimeren oder monomeren aciden Metallkomplex steht,
n die Anzahl der Metallkomplexe Mb und
m die Anzahl der Metallkomplexe Ms bedeutet, mit den Maßgaben, daß
mindestens ein Metallkomplex Mb oder Ms dimer sein muß, und daß die
Metallkomplexe Mb protonierbare Gruppen und die Metallkomplexe Ms
deprotonierbare Gruppen enthalten.in which
Mb stands for a dimeric or monomeric basic metal complex,
Ms represents a dimeric or monomeric acidic metal complex,
n the number of metal complexes Mb and
m denotes the number of metal complexes Ms, with the provisos that at least one metal complex Mb or Ms must be dimeric and that the metal complexes Mb contain protonatable groups and the metal complexes Ms deprotonable groups.
Bei dieser Methode ist es möglich, Ionenpaare zu erhalten, deren Metalle im kationischen Metallkomplex Mk und im anionischen Metallkomplex Ma verschieden sein können.With this method it is possible to obtain ion pairs whose metals are in the cationic metal complex Mk and different in the anionic metal complex Ma could be.
Da die Anzahl der Metallkomplexe Mb und die daraus hervorgehende Anzahl der kationischen Metallkomplexe Mk identisch sein müssen, wurde für beide Angaben die Variable n gewählt.Since the number of metal complexes Mb and the resulting number of cationic metal complexes Mk must be identical for both statements chosen the variable n.
Da die Anzahl der Metallkomplexe Ms und die Anzahl der daraus hervorgehenden anionischen Metallkomplexe Ma identisch sein müssen, wurde für beide Angaben die Variable m gewählt. Because the number of metal complexes Ms and the number of resulting anionic metal complexes Ma must be identical, was the for both statements Variable m selected.
Die Komplexbildner für beide Komponenten werden gemischt und das Metall in einem geeigneten Lösungsmittel wie zum Beispiel Wasser bei Temperaturen von Raumtemperatur bis 100°C eingeführt. Bei dieser Methode können Ionenpaare erhalten werden, in denen die Metalle im kationischen und im anionischen Komplex gleich sind.The complexing agents for both components are mixed and the metal in a suitable solvent such as water at temperatures of Room temperature up to 100 ° C introduced. With this method ion pairs can are obtained in which the metals in the cationic and in the anionic complex are the same.
Die Einführung der gewünschten Metallionen erfolgt in der Weise, wie sie z. B. in der Deutschen Offenlegungsschrift 34 01 052 offenbart worden ist, indem das Metalloxid oder ein Metallsalz (beispielsweise das Nitrat, Acetat, Carbonat, Chlorid oder Sulfat) des Elements der Ordnungszahlen 20-32, 39-51 oder 57-83 in Wasser und/oder einem niederen Alkohol (wie z. B. Methanol, Ethanol oder Isopropanol) gelöst oder suspendiert wird und mit der Lösung oder Suspension der äquivalenten Menge des komplexbildenden Liganden umgesetzt wird.The introduction of the desired metal ions takes place in the manner in which, for. B. in the German Offenlegungsschrift 34 01 052 has been disclosed by the metal oxide or a metal salt (e.g. the nitrate, acetate, carbonate, chloride or sulfate) the element of atomic numbers 20-32, 39-51 or 57-83 in water and / or dissolved in a lower alcohol (such as methanol, ethanol or isopropanol) or is suspended and with the solution or suspension of the equivalent amount of complex-forming ligand is implemented.
Die Herstellung der dimeren, cyclischen Komplexbildner, die durch einen Linker verknüpft sind, kann durch Umsetzung geeigneter Cyclenbausteine mit einem geeigneten Dielektrophil (z. B. einem Dibromid oder einem Diepoxid) unter Verwendung geeigneter Hilfsbasen (z. B. Alkalihydroxide, Alkalicarbonate) oder geeigneter Katalysatoren (z. B. Lithiumchlorid) oder des Cyclenbausteins im Überschuß erfolgen. (Literatur: MRM 35: 928 (1996); WO 95/07270; EP 0485045; EP 0255471).The preparation of the dimeric, cyclic complexing agent by a linker can be linked by implementing suitable cycle building blocks with a suitable dielectrophile (e.g. a dibromide or a diepoxide) Use of suitable auxiliary bases (e.g. alkali hydroxides, alkali carbonates) or suitable catalysts (e.g. lithium chloride) or the cyclic building block in the Surplus. (Literature: MRM 35: 928 (1996); WO 95/07270; EP 0485045; EP 0255471).
Die Herstellung der gebrauchsfertigen pharmazeutischen Mittel kann in Analogie zu den in der EP 0405704 genannten Methoden erfolgen. Die dort genannten pharmazeutischen Zusatzstoffe können zur Herstellung der erfindungsgemäßen Mittel verwendet werden.The preparation of the ready-to-use pharmaceutical agents can be made in analogy to the methods mentioned in EP 0405704. The ones mentioned there Pharmaceutical additives can be used to produce the inventive Funds are used.
Die erfindungsgemäßen pharmazeutischen Mittel enthalten vorzugsweise 1 µMol-5 Mol/l des Komplexsalzes und werden in der Regel in Mengen von 0,001-20 mMol/kg dosiert. Sie sind zur enteralen und parenteralen Applikation bestimmt.The pharmaceutical compositions according to the invention preferably contain 1 μmol-5 Mol / l of the complex salt and are usually in amounts of 0.001-20 doses of mmol / kg. They are intended for enteral and parenteral administration.
Die folgenden Beispiele sollen den Erfindungsgegenstand erläutern, ohne ihn auf diese beschränken zu wollen.The following examples are intended to illustrate the subject matter of the invention without excluding it want to limit them.
18 g (60 mmol) 4-Aza-N-benzyl-heptandisäurediethylester (Chem. Ber. 124, 487,
1991) werden in 20 ml Tetrahydrofuran gelöst, auf -78°C abgekühlt und
tropfenweise mit 12,8 ml Lithiumdiisopropylamid in Tetrahydrofuran (zweimolar)
versetzt. Nach weiteren 45 Minuten bei tiefer Temperatur addiert man 15,2 ml (120
mmol) Trimethylsilylchlorid (in 15 ml Tetrahydrofuran). Nach 30 Minuten gibt man 6,1
ml Brom in 61 ml Hexan hinzu. Nach einer Stunde Reaktionszeit versetzt man mit
100 ml 10%iger Salzsäure und läßt auf Raumtemperatur kommen. Man trennt die
Phasen und extrahiert die wäßrige Phase mit Essigsäureethylester. Die organischen
Phasen werden mit gesättigter Natriumchloridlösung gewaschen und über
Natriumsulfat getrocknet. Nach dem Filtrieren und Eindampfen erhält man ein
gelbliches Öl.
Ausbeute: 25,6 g (92% der Theorie)
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 43,89; H 4,98; N 3,01; O 13,76; Br 34,35;
gefunden:
C 44,02; H 5,11; N 2,93; Br 34,18.
18 g (60 mmol) of 4-aza-N-benzyl-heptanedioic acid diethyl ester (Chem. Ber. 124, 487, 1991) are dissolved in 20 ml of tetrahydrofuran, cooled to -78 ° C and added dropwise with 12.8 ml of lithium diisopropylamide in tetrahydrofuran ( two molar). After a further 45 minutes at low temperature, 15.2 ml (120 mmol) of trimethylsilyl chloride (in 15 ml of tetrahydrofuran) are added. After 30 minutes, 6.1 ml of bromine in 61 ml of hexane are added. After an hour of reaction, 100 ml of 10% hydrochloric acid are added and the mixture is allowed to come to room temperature. The phases are separated and the aqueous phase is extracted with ethyl acetate. The organic phases are washed with saturated sodium chloride solution and dried over sodium sulfate. After filtering and evaporating, a yellowish oil is obtained.
Yield: 25.6 g (92% of theory)
Analysis (based on solvent-free substance):
calculated:
C 43.89; H 4.98; N 3.01; O 13.76; Br 34.35;
found:
C 44.02; H 5.11; N 2.93; Br 34.18.
20,7 g (120 mmol) 1,4,7,10-Tetraazacyclododecan werden in 410 ml Chloroform bei
Raumtemperatur gelöst und mit 100 mg Natriumiodid versetzt. Anschließend setzt
man 9,3 g (20 mmol) 4-Aza-N-benzyl-2,6-dibrom-heptandisäurediethylester in 190 ml
Chloroform tropfenweise zu. Man rührt zwei Tage bei Raumtemperatur, filtriert den
Niederschlag ab und wäscht das Filtrat mit Wasser. Die organische Phase wird über
Natriumsulfat getrocknet, filtriert und eingedampft.
Ausbeute: 8,7 g (67,1% der Theorie) gelblicher Feststoff.
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 61,18; H 9,49; N 19,46; O 9,88;
gefunden:
C 61,03; H 9,66; N 19,28.20.7 g (120 mmol) 1,4,7,10-tetraazacyclododecane are dissolved in 410 ml chloroform at room temperature and 100 mg sodium iodide are added. Then 9.3 g (20 mmol) of diethyl 4-aza-N-benzyl-2,6-dibromo-heptanedioate are added dropwise in 190 ml of chloroform. The mixture is stirred at room temperature for two days, the precipitate is filtered off and the filtrate is washed with water. The organic phase is dried over sodium sulfate, filtered and evaporated.
Yield: 8.7 g (67.1% of theory) of a yellowish solid.
Analysis (based on solvent-free substance):
calculated:
C 61.18; H 9.49; N 19.46; O 9.88;
found:
C 61.03; H 9.66; N 19.28.
Zu 0,8 g (21,7 mmol) Lithiumaluminiumhydrid in 40 ml Diethylether werden bei 0°C
langsam 8,4 g (13 mmol) 1,1'-[3-Aza-N-benzyl-1,5-bis-(ethoxycarbonyl)-1,5-
pentandiyl]-bis-[1,4,7,10-tetraazacyclododecan] in 15 ml Diethylether getropft. Die
Reaktionsmischung wird 14 Stunden bei Raumtemperatur gerührt und dann
vorsichtig mit Wasser hydrolisiert. Man filtriert, wäscht den Niederschlag mehrmals
mit Diethylether, trennt die Phasen und trocknet die organische Phase über
Natriumsulfat.
Ausbeute: 6,8 g (92,8% der Theorie) farbloses Öl.
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 61,78; H 10,19; N 22,36; O 5,68;
gefunden:
C 61,64; H 10,01; N 22,47.
8.4 g (13 mmol) of 1,1 '- [3-aza-N-benzyl-1,5-bis - are slowly added to 0.8 g (21.7 mmol) of lithium aluminum hydride in 40 ml of diethyl ether at 0 ° C. (Ethoxycarbonyl) -1,5-pentanediyl] bis- [1,4,7,10-tetraazacyclododecane] in 15 ml of diethyl ether. The reaction mixture is stirred for 14 hours at room temperature and then carefully hydrolyzed with water. It is filtered, the precipitate is washed several times with diethyl ether, the phases are separated and the organic phase is dried over sodium sulfate.
Yield: 6.8 g (92.8% of theory) of colorless oil.
Analysis (based on solvent-free substance):
calculated:
C 61.78; H 10.19; N 22.36; O 5.68;
found:
C 61.64; H 10.01; N 22.47.
6,7 g (12 mmol) 1,1'-[4-Aza-N-benzyl-1,7-dihydroxy-2,6-pentandiyl]-bis-[1,4,7,10-
tetraazacyclododecan] werden in 85 ml Acetonitril gelöst und bei Raumtemperatur
mit 3,3 ml (18 mmol) Diisopropylethylamin und 14,75 g (75,6 mmol) Bromessigsäure-
tert.-butylester versetzt. Der Ansatz wird 20 Stunden bei 60°C gerührt und
anschließend 48 Stunden bei Raumtemperatur nachgerührt. Anschließend wird die
Suspension zur Trockne eingedampft und der Rückstand in Diethylether
aufgenommen. Man wäscht die organische Phase mit Wasser, trocknet über
Natriumsulfat und dampft das Filtrat ein. Zur Reinigung wird der Rückstand an
Kieselgel chromatographiert.
Ausbeute: 13,8 g (92,1% der Theorie) farbloses Öl.
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 62,52; H 9,44; N 10,10; O 17,94;
gefunden:
C 62,39; H 9,58; N 9,86.6.7 g (12 mmol) of 1,1 '- [4-aza-N-benzyl-1,7-dihydroxy-2,6-pentanediyl] -bis- [1,4,7,10-tetraazacyclododecane] are described in 85 ml of acetonitrile were dissolved and 3.3 ml (18 mmol) of diisopropylethylamine and 14.75 g (75.6 mmol) of tert-butyl bromoacetate were added at room temperature. The mixture is stirred at 60 ° C. for 20 hours and then stirred at room temperature for 48 hours. The suspension is then evaporated to dryness and the residue is taken up in diethyl ether. The organic phase is washed with water, dried over sodium sulfate and the filtrate is evaporated. The residue is chromatographed on silica gel for purification.
Yield: 13.8 g (92.1% of theory) of colorless oil.
Analysis (based on solvent-free substance):
calculated:
C 62.52; H 9.44; N 10.10; O 17.94;
found:
C 62.39; H 9.58; N 9.86.
13,7 g (11 mmol) 1,1'-[4-Aza-N-benzyl-1,7-dihydroxy-2,6-pentandiyl]-bis-[(4,7,10-tris-
tert.-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecan] werden in 270 ml
Ethanol gelöst und unter Zusatz von 2,7 g Palladium auf Aktivkohle bei
Raumtemperatur und Normaldruck hydriert. Man filtriert vom Katalysator und dampft
den Rückstand ein.
Ausbeute: 12,1 g (94,9% der Theorie) farbloses Öl.
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 60,13; H 9,66; N 10,88; O 19,33;
gefunden:
C 60,02; H 9,49; N 10,63.
13.7 g (11 mmol) 1,1 '- [4-aza-N-benzyl-1,7-dihydroxy-2,6-pentanediyl] -bis - [(4,7,10-tristert.- butoxycarbonylmethyl) -1,4,7,10-tetraazacyclododecane] are dissolved in 270 ml of ethanol and hydrogenated with addition of 2.7 g of palladium on activated carbon at room temperature and normal pressure. The catalyst is filtered off and the residue is evaporated.
Yield: 12.1 g (94.9% of theory) of colorless oil.
Analysis (based on solvent-free substance):
calculated:
C 60.13; H 9.66; N 10.88; O 19.33;
found:
C 60.02; H 9.49; N 10.63.
Zu einer unter Feuchtigkeitsausschluß gerührten Suspension von 11,9 g (9,5 mmol)
1,1'-[4-Aza-1,7-dihydroxy-2,6-pentandiyl]-bis-[(4,7,10-tris-tert.-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecan] in 100 ml wasserfreiem
Dioxan werden 1,28 g (11 mmol) Diglykolsäureanhydrid bei Raumtemperatur
zugegeben. Der Ansatz wird sechs Stunden bei Raumtemperatur gerührt und
anschließend eingedampft. Man nimmt den Rückstand in halbnormaler Natronlauge
auf, extrahiert mit Essigsäureethylester und fällt die Säure mit konzentrierter
Salzsäure bei pH 2,5 aus der wäßrigen Phase.
Ausbeute: 10,6 g (87,5% d. Theorie) farbloser Feststoff.
Analyse (bezogen auf lösungsmittelfreie Substanz):
berechnet:
C 58,42; H 9,09; N 9,89; O 22,59;
gefunden:
C 58,24; H 9,21; N 9,63.To a suspension of 11.9 g (9.5 mmol) of 1,1 '- [4-aza-1,7-dihydroxy-2,6-pentanediyl] -bis - [(4,7,10- tris-tert-butoxycarbonylmethyl) -1,4,7,10-tetraazacyclododecane] in 100 ml of anhydrous dioxane, 1.28 g (11 mmol) of diglycolic anhydride are added at room temperature. The mixture is stirred at room temperature for six hours and then evaporated. The residue is taken up in semi-normal sodium hydroxide solution, extracted with ethyl acetate and the acid is precipitated from the aqueous phase with concentrated hydrochloric acid at pH 2.5.
Yield: 10.6 g (87.5% of theory) of a colorless solid.
Analysis (based on solvent-free substance):
calculated:
C 58.42; H 9.09; N 9.89; O 22.59;
found:
C 58.24; H 9.21; N 9.63.
10,4 g (9 mmol) 1,1'-[4-Aza-1,7-dihydroxy-2,6-pentandiyl]-bis-[(4,7,10-tris-tert.-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecan] werden in 60 ml
Trifluoressigsäure gelöst und 20 Stunden bei Raumtemperatur gerührt. Zur
Aufarbeitung verdünnt man mit Wasser und dampft zur Trockne ein. Dieser Vorgang
wird mehrmals wiederholt. Anschließend wird eine wäßrige Lösung des Produktes
über eine Anionenaustauschersäule gereinigt und die produkthaltigen Fraktionen
eingedampft. Die Hexacarbonsäure wird mit 3,36 g (9 mmol) Dysprosiumoxid
komplexiert, filtriert und die wäßrige Lösung anschließend gefriergetrocknet.
Ausbeute: 9,6 g (93,5% der Theorie) farbloses Lyophilisat.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 35,80; H 5,04; N 11,05; O 19,63; Dy 28,49;
gefunden:
C 35,68; H 5,20; N 10,93; Dy 28,27.10.4 g (9 mmol) of 1,1 '- [4-aza-1,7-dihydroxy-2,6-pentanediyl] bis - [(4,7,10-tris-tert-butoxycarbonylmethyl) -1 , 4,7,10-tetraazacyclododecane] are dissolved in 60 ml of trifluoroacetic acid and stirred for 20 hours at room temperature. For working up, dilute with water and evaporate to dryness. This process is repeated several times. Then an aqueous solution of the product is purified on an anion exchange column and the product-containing fractions are evaporated. The hexacarboxylic acid is complexed with 3.36 g (9 mmol) of dysprosium oxide, filtered and the aqueous solution is then freeze-dried.
Yield: 9.6 g (93.5% of theory) of colorless lyophilisate.
Analysis (based on anhydrous substance):
calculated:
C 35.80; H 5.04; N 11.05; O 19.63; Dy 28.49;
found:
C 35.68; H 5.20; N 10.93; Dy 28.27.
10,2 g (8 mmol) 1,1'-[4-Aza-N-(4-carboxy-3-oxa-1-oxo-butyl)-1,7-dihydroxy-2,6-
pentandiyl]-bis-[(4,7,10-tris-tert.-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecan] werden in 60 ml Trifluoressigsäure gelöst und 16 Stunden bei
Raumtemperatur gerührt. Zur Aufarbeitung verdünnt man mit Wasser und dampft zur
Trockne ein. Dieser Vorgang wird mehrmals wiederholt. Anschließend wird eine
wäßrige Lösung des Produktes über eine Anionenaustauschersäule gereinigt und
die produkthaltigen Fraktionen eingedampft. Die Hexacarbonsäure wird mit 2,98 g (8
mmol) Dysprosiumoxid komplexiert, filtriert und die wäßrige Lösung anschließend
gefriergetrocknet.
Ausbeute: 9,3 g (92,5% der Theorie) farbloses Lyophilisat.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 36,31; H 4,89; N 10,03; O 22,91; Dy 25,86;
gefunden:
C 36,20; H 5,13; N 9,89; Dy 25,67.10.2 g (8 mmol) 1,1 '- [4-aza-N- (4-carboxy-3-oxa-1-oxo-butyl) -1,7-dihydroxy-2,6-pentanediyl] bis - [(4,7,10-tris-tert-butoxycarbonylmethyl) -1,4,7,10-tetraazacyclododecane] are dissolved in 60 ml of trifluoroacetic acid and stirred for 16 hours at room temperature. For working up, dilute with water and evaporate to dryness. This process is repeated several times. Then an aqueous solution of the product is purified on an anion exchange column and the product-containing fractions are evaporated. The hexacarboxylic acid is complexed with 2.98 g (8 mmol) of dysprosium oxide, filtered and the aqueous solution is then freeze-dried.
Yield: 9.3 g (92.5% of theory) of colorless lyophilisate.
Analysis (based on anhydrous substance):
calculated:
C 36.31; H 4.89; N 10.03; O 22.91; Dy 25.86;
found:
C 36.20; H 5.13; N 9.89; Dy 25.67.
6,28 g (5 mmol) 1,1'-[1,7-Dihydroxy-4-aza-N-(4-carboxy-3-oxa-1-oxo-butyl)-2,6-
heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-
Dysprosiumkomplex werden in 75 ml Wasser gelöst und mit 1,1'-[1,7-Dihydroxy-4-
aza-2,6-heptandiyl]-bis-[(4,7,10-triscarboxymethyl)-1,4,7,10-tetraazacyclododecan],
Di-Dysprosiumkomplex neutralisiert. Die fertige Salzlösung wird mit Aktivkohle
gereinigt, filtriert und gefriergetrocknet.
Ausbeute: 11,7 g (97,6% der Theorie) farbloses Lyophilisat.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 36,05; H 4,96; N 10,54; O 21,27; Dy 27,17;
gefunden:
C 35,93; H 5,08; N 10,37; Dy 27,02.6.28 g (5 mmol) of 1,1 '- [1,7-dihydroxy-4-aza-N- (4-carboxy-3-oxa-1-oxo-butyl) -2,6-heptanediyl] bis - [(4,7,10-triscarboxymethyl) -1,4,7,10-tetraazacyclododecane], di-dysprosium complex are dissolved in 75 ml of water and mixed with 1,1 '- [1,7-dihydroxy-4-aza- 2,6-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) -1,4,7,10-tetraazacyclododecane], di-dysprosium complex neutralized. The finished salt solution is cleaned with activated carbon, filtered and freeze-dried.
Yield: 11.7 g (97.6% of theory) of colorless lyophilisate.
Analysis (based on anhydrous substance):
calculated:
C 36.05; H 4.96; N 10.54; O 21.27; Dy 27.17;
found:
C 35.93; H 5.08; N 10.37; Dy 27.02.
Nach portionsweiser Zugabe von 4,3 g (20.0 mmol) Benzyl-bis-oxiranylmethylamin
(P.M. Zavlin et al., J. Appl. Chem. USSR, 59 (1986) 1317) zu einer Lösung von 20,0
g (45,0 mmol) 1,4,7,10-Tetraazacyclododecan-1,4,7-triessigsäure-Dihydrogensulfat
(D. D. Dischino et al., Inorg. Chem. 30 (1991) 1265) in 40 ml 5 N Natronlauge wird 5
Stunden bei 70°C gerührt. Anschließend wird durch Zugabe von halbkonzentrierter
Salzsäure pH 2 eingestellt und nach Zugabe von 8,33 g (23,0 mmol) Gadoliniumoxid
2 Stunden refluxiert. Dann wird eingedampft und der Rückstand über Kieselgel mit
Chloroform/Methanol/Ammoniak chromatographiert. Die das Produkt enthaltenden
Fraktionen werden zur Trockne eingedampft, in heißem Ethanol aufgenommen und
filtriert. Das Filtrat wird vollständig eingedampft und der Rückstand aus
Isopropanol/Wasser umkristallisiert.
Ausbeute: 15,6 g (61,0% der Theorie) farbloser Feststoff.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 43,15; H 4,96; N 9,84; O 17,49; Gd 24,56;
gefunden:
C 43,34; H 5,32; N 10,02; Gd 24,34.After portionwise addition of 4.3 g (20.0 mmol) of benzyl-bis-oxiranylmethylamine (PM Zavlin et al., J. Appl. Chem. USSR, 59 (1986) 1317) to a solution of 20.0 g (45.0 mmol) 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid dihydrogen sulfate (DD Dischino et al., Inorg. Chem. 30 (1991) 1265) in 40 ml of 5 N sodium hydroxide solution for 5 hours at 70 ° C stirred. The pH is then adjusted to 2 by adding half-concentrated hydrochloric acid and, after the addition of 8.33 g (23.0 mmol) of gadolinium oxide, is refluxed for 2 hours. Then it is evaporated and the residue is chromatographed on silica gel with chloroform / methanol / ammonia. The fractions containing the product are evaporated to dryness, taken up in hot ethanol and filtered. The filtrate is evaporated completely and the residue is recrystallized from isopropanol / water.
Yield: 15.6 g (61.0% of theory) of a colorless solid.
Analysis (based on anhydrous substance):
calculated:
C 43.15; H 4.96; N 9.84; O 17.49; Gd 24.56;
found:
C 43.34; H 5.32; N 10.02; Gd 24.34.
14,3 g (11,2 mmol) 1,1'-[4-Benzyl-2,6-dihydroxy-4-aza-1,7-heptandiyl]-bis-[(4,7,10-
triscarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-Gadoliniumkomplex werden in
140 ml wässrigem Methanol gelöst und nach Zugabe von 1,5 g Palladium (10%) auf
Aktivkohle mit Wasserstoff hydriert. Nach Filtrieren wird das Filtrat bis zur Trockne
eingedampft.
Ausbeute: 12,7 g (100% der Theorie) farbloser Feststoff.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 36,13; H 5,08; N 11,15; O 19,82; Gd 27,82;
gefunden:
C 36,47; H 5,15; N 11,36; Gd 27,70.14.3 g (11.2 mmol) of 1,1 '- [4-benzyl-2,6-dihydroxy-4-aza-1,7-heptanediyl] -bis - [(4,7,10-triscarboxymethyl) - 1,4,7,10-tetraazacyclododecane], di-gadolinium complex are dissolved in 140 ml of aqueous methanol and hydrogenated with hydrogen after the addition of 1.5 g of palladium (10%) on activated carbon. After filtering, the filtrate is evaporated to dryness.
Yield: 12.7 g (100% of theory) of a colorless solid.
Analysis (based on anhydrous substance):
calculated:
C 36.13; H 5.08; N 11.15; O 19.82; Gd 27.82;
found:
C 36.47; H 5.15; N 11.36; Gd 27.70.
10,4 g (9,2 mmol) 1,1'-[2,6-Dihydroxy-4-aza-1,7-heptandiyl]-bis-[(4,7,10-
tricarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-Gadoliniumkomplex werden in
100 ml Wasser gelöst und nach Zugabe von 1,38 g (11,0 mmol) 2-Bromethanol bei
50°C gerührt. Über einen Zeitraum von 2 Stunden gibt man 5,0 ml 2N Natronlauge
zu und läßt weitere 2 Stunden bei 50°C nachrühren. Anschließend wird die Lösung
im Vakuum eingedampft und über Kieselgel RP-18 chromatographiert
(Elutionsmittel: Wasser/Acetonitril). Die das Produkt enthaltenden Fraktionen werden
eingedampft und der Rückstand am Hochvakuum getrocknet.
Ausbeute: 8,5 g (78,4% der Theorie) farbloser Feststoff.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 36,82; H 5,24; N 10,73; O 20,43; Gd 26,78;
gefunden:
C 36,91; H 5,65; N 10,89; Gd 26,52.10.4 g (9.2 mmol) 1,1 '- [2,6-dihydroxy-4-aza-1,7-heptanediyl] -bis - [(4,7,10-tricarboxymethyl) -1,4, 7,10-tetraazacyclododecane], di-gadolinium complex are dissolved in 100 ml of water and, after adding 1.38 g (11.0 mmol) of 2-bromoethanol, stirred at 50 ° C. 5.0 ml of 2N sodium hydroxide solution are added over a period of 2 hours and the mixture is stirred at 50 ° C. for a further 2 hours. The solution is then evaporated in vacuo and chromatographed on silica gel RP-18 (eluent: water / acetonitrile). The fractions containing the product are evaporated and the residue is dried under high vacuum.
Yield: 8.5 g (78.4% of theory) of a colorless solid.
Analysis (based on anhydrous substance):
calculated:
C 36.82; H 5.24; N 10.73; O 20.43; Gd 26.78;
found:
C 36.91; H 5.65; N 10.89; Gd 26.52.
11,0 g (9,73 mmol) 1,1'-[2,6-Dihydroxy-4-aza-1,7-heptandiyl]-bis-[(4,7,10-
tricarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-Gadoliniumkomplex werden in
100 ml Wasser gelöst und nach Zugabe von 2,67 g (15,0 mmol)
Chlorsulfonylessigsäurechlorid bei 0°C gerührt. Über einen Zeitraum von 2 Stunden
gibt man 30,0 ml 2N Natronlauge zu und läßt weitere 2 Stunden bei Raumtemperatur
nachrühren. Anschließend wird die Lösung im Vakuum eingedampft und über
Kieselgel RP-18 chromatographiert (Elutionsmittel: Wasser/Acetonitril). Die das
Produkt enthaltenden Fraktionen werden eingedampft und der Rückstand am
Hochvakuum getrocknet.
Ausbeute: 9,9 g (81,3% der Theorie) farbloser Feststoff.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 34,52; H 4,75; N 10,07; O 22,99; S 2,56; Gd 26,78;
gefunden:
C 34,67; H 4,99; N 10,23; S 2,38; Gd 26,52.11.0 g (9.73 mmol) 1,1 '- [2,6-dihydroxy-4-aza-1,7-heptanediyl] -bis - [(4,7,10-tricarboxymethyl) -1,4, 7,10-tetraazacyclododecane], di-gadolinium complex are dissolved in 100 ml of water and, after adding 2.67 g (15.0 mmol) of chlorosulfonyl acetic acid chloride, stirred at 0 ° C. 30.0 ml of 2N sodium hydroxide solution are added over a period of 2 hours and the mixture is stirred for a further 2 hours at room temperature. The solution is then evaporated in vacuo and chromatographed on silica gel RP-18 (eluent: water / acetonitrile). The fractions containing the product are evaporated and the residue is dried under high vacuum.
Yield: 9.9 g (81.3% of theory) of a colorless solid.
Analysis (based on anhydrous substance):
calculated:
C 34.52; H 4.75; N 10.07; O 22.99; S 2.56; Gd 26.78;
found:
C 34.67; H 4.99; N 10.23; S 2.38; Gd 26.52.
5,0 g (4,25 mmol) 1,1'-[4-(2-Hydroxyethyl)-2,6-dihydroxy-4-aza-1,7-heptandiyl]-bis-
[(4,7,10-tricarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-Gadoliniumkomplex
werden in 50 ml Wasser gerührt und mit 1,1'-[2,6-Dihydroxy-4-aza-4-sulfoacetyl-1,7-
heptandiyl]-bis-[(4,7,10-tricarboxymethyl)-1,4,7,10-tetraazacyclododecan], Di-
Gadoliniumkomplex versetzt bis der Neutralpunkt erreicht ist. Man erhält eine
Lösung, die anschließend gefriergetrocknet wird.
Ausbeute: 10,3 g (100% d. Theorie) farbloses Lyophilisat.
Analyse (bezogen auf wasserfreie Substanz):
berechnet:
C 35,63; H 4,98; N 10,39; O 21,75; S 1,32; Gd 25,92;
gefunden:
C 35,67; H 5,12; N 10,53; S 1,12; Gd 26,13.5.0 g (4.25 mmol) of 1,1 '- [4- (2-hydroxyethyl) -2,6-dihydroxy-4-aza-1,7-heptanediyl] -bis- [(4,7,10 -tricarboxymethyl) -1,4,7,10-tetraazacyclododecane], di-gadolinium complex are stirred in 50 ml of water and mixed with 1,1 '- [2,6-dihydroxy-4-aza-4-sulfoacetyl-1,7- heptanediyl] -bis - [(4,7,10-tricarboxymethyl) -1,4,7,10-tetraazacyclododecane], di-gadolinium complex added until the neutral point is reached. A solution is obtained which is then freeze-dried.
Yield: 10.3 g (100% of theory) of colorless lyophilisate.
Analysis (based on anhydrous substance):
calculated:
C 35.63; H 4.98; N 10.39; O 21.75; S 1.32; Gd 25.92;
found:
C 35.67; H 5.12; N 10.53; S 1.12; Gd 26.13.
Claims (20)
Mk e|n Ma f|m (I)
worin
Mk für einen dimeren oder monomeren cyclischen kationischen Metallkomplex steht,
Ma für einen dimeren oder monomeren cyclischen anionischen Metallkomplex steht,
mit der Maßgabe, daß mindestens ein Metallkomplex Mk oder Ma dimer sein muß,
e für die elektrische Ladung von Mk steht,
f für die elektrische Ladung von Ma steht,
n für die Anzahl der Ionen Mk steht und
m für die Anzahl der Ionen Ma steht.1. Dimer ion pairs of the general formula (I)
Mk e | n Ma f | m (I)
wherein
Mk represents a dimeric or monomeric cyclic cationic metal complex,
Ma represents a dimeric or monomeric cyclic anionic metal complex,
with the proviso that at least one metal complex must be Mk or Ma dimer,
e represents the electrical charge of Mk,
f represents the electrical charge of Ma,
n stands for the number of ions Mk and
m stands for the number of ions Ma.
Mk e|n Ma f|m (I)
worin
Mk für einen dimeren oder monomeren cyclischen kationischen Metallkomplex steht,
Ma für einen dimeren oder monomeren cyclischen anionischen Metallkomplex steht,
mit den Maßgaben, daß mindestens ein Metallkomplex Mk oder Ma dimer sein muß, und daß die Metallkomplexe Mk protonierte Gruppen und die Metallkomplexe Ma deprotonierte Gruppen enthalten,
e für die elektrische Ladung von Mk steht,
f für die elektrische Ladung von Ma steht,
n für die Anzahl der Ionen Mk steht und
m für die Anzahl der Ionen Ma steht. 2. Dimer ion pairs of the general formula (I)
Mk e | n Ma f | m (I)
wherein
Mk represents a dimeric or monomeric cyclic cationic metal complex,
Ma represents a dimeric or monomeric cyclic anionic metal complex,
with the provisos that at least one metal complex Mk or Ma must be dimeric and that the metal complexes Mk contain protonated groups and the metal complexes Ma deprotonate groups,
e represents the electrical charge of Mk,
f represents the electrical charge of Ma,
n stands for the number of ions Mk and
m stands for the number of ions Ma.
ist, worin
L eine C2-C9-Alkylengruppe bedeutet, die gegebenenfalls durch 1-2 Sauerstoffatome und/oder 1-3 Stickstoffatome unterbrochen sein kann und/oder mit 1-5 Hydroxygruppen und/oder gegebenenfalls mit 1-3 geradkettigen oder verzweigten C1-C7-Acyl- und/oder C1-C7-Alkylgrupen, die jeweils gegebenenfalls durch 1-3 Sauerstoffatome und/oder 1-2 Stickstoffatome unterbrochen sind und/oder gegebenenfalls 1-5 Hydroxygruppen und/oder gegebenenfalls 1-2 Carboxy-, Phosphonat- oder Sulfonylreste enthalten, substituiert sein kann. 6. Dimer ion pairs according to claim 1 and 2, characterized in that the complexing agent of the dimeric metal complex ion Mk and / or Ma is a compound of general formula II
is what
L is a C 2 -C 9 alkylene group which can optionally be interrupted by 1-2 oxygen atoms and / or 1-3 nitrogen atoms and / or with 1-5 hydroxy groups and / or optionally with 1-3 straight-chain or branched C 1 - C 7 -acyl and / or C 1 -C 7 -alkyl groups, which are each optionally interrupted by 1-3 oxygen atoms and / or 1-2 nitrogen atoms and / or optionally 1-5 hydroxyl groups and / or optionally 1-2 carboxy- , Contain phosphonate or sulfonyl radicals, may be substituted.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998149465 DE19849465A1 (en) | 1998-10-21 | 1998-10-21 | New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998149465 DE19849465A1 (en) | 1998-10-21 | 1998-10-21 | New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19849465A1 true DE19849465A1 (en) | 2000-04-27 |
Family
ID=7885777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1998149465 Withdrawn DE19849465A1 (en) | 1998-10-21 | 1998-10-21 | New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agents |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19849465A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10117242C1 (en) * | 2001-04-06 | 2002-05-16 | Schering Ag | New dimeric tetraazacyclododecane derivatives and their metal complexes useful as components of diagnostic agents, especially X-ray contrast agents, and radiotherapeutics |
WO2004006934A2 (en) * | 2002-07-10 | 2004-01-22 | Hans Robert Kalbitzer | 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours |
WO2006002874A1 (en) * | 2004-07-02 | 2006-01-12 | Bracco Imaging Spa | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain 1, 4, 7, 10-tertraazacyclodecan-1, 4, 7-triacetic acid chelating moiety with polyhydroxylated substituents |
WO2010011367A2 (en) * | 2008-02-22 | 2010-01-28 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
WO2017098044A1 (en) * | 2015-12-10 | 2017-06-15 | Bracco Imaging Spa | Dimeric contrast agents |
WO2017178301A1 (en) * | 2016-04-13 | 2017-10-19 | Bracco Imaging Spa | Contrast agents |
WO2018108780A1 (en) | 2016-12-12 | 2018-06-21 | Bracco Imaging Spa | Dimeric contrast agents |
CN108290849A (en) * | 2015-12-10 | 2018-07-17 | 伯拉考成像股份公司 | Contrast agent |
US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
US10441669B2 (en) | 2013-10-04 | 2019-10-15 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
US10556873B2 (en) | 2008-02-22 | 2020-02-11 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
WO2024074648A1 (en) * | 2022-10-07 | 2024-04-11 | Bracco Imaging Spa | Precipitation and isolation of gadolinium complex |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255471A1 (en) * | 1986-07-28 | 1988-02-03 | Schering Aktiengesellschaft | 1,4,7,10-Tetraazacyclododecane-derivatives |
EP0485045A2 (en) * | 1990-11-08 | 1992-05-13 | Schering Aktiengesellschaft | Mono-N-substituted 1,4,7,10-Tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them |
WO1995007270A1 (en) * | 1993-09-07 | 1995-03-16 | Nycomed Salutar, Inc. | Chelants as contrast enhancing agents |
-
1998
- 1998-10-21 DE DE1998149465 patent/DE19849465A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255471A1 (en) * | 1986-07-28 | 1988-02-03 | Schering Aktiengesellschaft | 1,4,7,10-Tetraazacyclododecane-derivatives |
EP0485045A2 (en) * | 1990-11-08 | 1992-05-13 | Schering Aktiengesellschaft | Mono-N-substituted 1,4,7,10-Tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them |
WO1995007270A1 (en) * | 1993-09-07 | 1995-03-16 | Nycomed Salutar, Inc. | Chelants as contrast enhancing agents |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10117242C1 (en) * | 2001-04-06 | 2002-05-16 | Schering Ag | New dimeric tetraazacyclododecane derivatives and their metal complexes useful as components of diagnostic agents, especially X-ray contrast agents, and radiotherapeutics |
WO2004006934A2 (en) * | 2002-07-10 | 2004-01-22 | Hans Robert Kalbitzer | 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours |
WO2004006934A3 (en) * | 2002-07-10 | 2004-04-01 | Hans Robert Kalbitzer | 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours |
WO2006002874A1 (en) * | 2004-07-02 | 2006-01-12 | Bracco Imaging Spa | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain 1, 4, 7, 10-tertraazacyclodecan-1, 4, 7-triacetic acid chelating moiety with polyhydroxylated substituents |
US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
WO2010011367A2 (en) * | 2008-02-22 | 2010-01-28 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
WO2010011367A3 (en) * | 2008-02-22 | 2010-03-25 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US9115094B2 (en) | 2008-02-22 | 2015-08-25 | The United States Of America, National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US10556873B2 (en) | 2008-02-22 | 2020-02-11 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
US10842893B2 (en) | 2013-10-04 | 2020-11-24 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
US10441669B2 (en) | 2013-10-04 | 2019-10-15 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
RU2739834C2 (en) * | 2015-12-10 | 2020-12-28 | Бракко Имэджинг Спа | Dimeric contrast agents |
US11021451B2 (en) | 2015-12-10 | 2021-06-01 | Bracco Imaging S.P.A. | Contrast agents |
US20180362511A1 (en) * | 2015-12-10 | 2018-12-20 | Bracco Imaging S.P.A. | Dimeric contrast agents |
JP2019501153A (en) * | 2015-12-10 | 2019-01-17 | ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. | Dimeric contrast agent |
CN108368067A (en) * | 2015-12-10 | 2018-08-03 | 伯拉考成像股份公司 | Dimerization contrast agent |
US11401262B2 (en) | 2015-12-10 | 2022-08-02 | Bracco Imaging S.P.A. | Dimeric contrast agents |
US10407412B2 (en) * | 2015-12-10 | 2019-09-10 | Bracco Imaging S.P.A. | Dimeric contrast agents |
CN108290849A (en) * | 2015-12-10 | 2018-07-17 | 伯拉考成像股份公司 | Contrast agent |
US20190345142A1 (en) * | 2015-12-10 | 2019-11-14 | Bracco Imaging S.P.A. | Dimeric contrast agents |
CN108368067B (en) * | 2015-12-10 | 2022-04-29 | 伯拉考成像股份公司 | Dimeric contrast agents |
CN108290849B (en) * | 2015-12-10 | 2022-03-22 | 伯拉考成像股份公司 | Contrast agents |
US10781188B2 (en) | 2015-12-10 | 2020-09-22 | Bracco Imaging S.P.A. | Contrast agents |
US10882849B2 (en) | 2015-12-10 | 2021-01-05 | Bracco Imaging S.P.A. | Dimeric contrast agents |
WO2017098044A1 (en) * | 2015-12-10 | 2017-06-15 | Bracco Imaging Spa | Dimeric contrast agents |
EP3753929A1 (en) | 2015-12-10 | 2020-12-23 | Bracco Imaging SPA | Dimeric contrast agents |
WO2017178301A1 (en) * | 2016-04-13 | 2017-10-19 | Bracco Imaging Spa | Contrast agents |
US11007283B2 (en) | 2016-04-13 | 2021-05-18 | Bracco Imaging S.P.A. | Contrast agents |
CN108779082A (en) * | 2016-04-13 | 2018-11-09 | 伯拉考成像股份公司 | contrast agent |
CN108779082B (en) * | 2016-04-13 | 2022-08-02 | 伯拉考成像股份公司 | Contrast agents |
US10793533B2 (en) | 2016-12-12 | 2020-10-06 | Bracco Imaging S.P.A. | Dimeric contrast agents |
AU2017375728B2 (en) * | 2016-12-12 | 2021-05-27 | Bracco Imaging Spa | Dimeric contrast agents |
WO2018108780A1 (en) | 2016-12-12 | 2018-06-21 | Bracco Imaging Spa | Dimeric contrast agents |
JP2020500917A (en) * | 2016-12-12 | 2020-01-16 | ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. | Dimer contrast agent |
CN109963838A (en) * | 2016-12-12 | 2019-07-02 | 伯拉考成像股份公司 | Dimerization contrast agent |
JP7145156B2 (en) | 2016-12-12 | 2022-09-30 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | dimer contrast agent |
CN109963838B (en) * | 2016-12-12 | 2023-04-11 | 伯拉考成像股份公司 | Dimeric contrast agents |
WO2024074648A1 (en) * | 2022-10-07 | 2024-04-11 | Bracco Imaging Spa | Precipitation and isolation of gadolinium complex |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0662972B1 (en) | 3-,8-substituted deuteroporphyrine derivatives, pharmaceuticals containing them and methods of producing them | |
EP0430863B2 (en) | Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same | |
DE3401052C2 (en) | Diagnostic agents | |
DE3855451T2 (en) | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | |
DE69018615T2 (en) | HETEROCYCLIC CHELATE-MAKING ACTIVE SUBSTANCES. | |
CA1341035C (en) | Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them. | |
DE4009119A1 (en) | 1,4,7,10-TETRAAZACYCLODODECANE-BUTYLTRIOLS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM | |
DE3887566T2 (en) | Pyridoxamine chelate compounds, manganese II chelates and their use as NMRI contrast agents. | |
DD293113A5 (en) | PROCESS FOR THE PRODUCTION OF COMPLEXES | |
EP0325559B1 (en) | Process for the preparation of complex compounds | |
DE3827940A1 (en) | 13,17-PROPIONIC ACID AND PROPIONIC ACID DERIVATIVE SUBSTITUTED PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM | |
DE19849465A1 (en) | New dimeric ion pairs containing cationic and anionic metal complexes; useful as low viscosity contrast agents for X-ray, magnetic resonance and radiodiagnostic techniques, and as radiotherapy agents | |
DE3852906T2 (en) | Dipyridoxyl phosphate as a magnetic resonance imaging agent. | |
DE4311023C2 (en) | Bifunctional chalcogen atom-interrupted chelating agents of type XN¶1¶S¶1¶O¶1¶ for radioactive isotopes, their metal complexes, processes for their preparation and pharmaceutical compositions containing them | |
US5645818A (en) | Diagnostic compositions comprising a complex formed by a nitrogenous macrocyclic ligand with metal ions | |
DE19719033C1 (en) | Ion pairs, processes for their preparation and their use as contrast agents | |
EP0775104B1 (en) | Dimer dtpa derivatives and their metal complexes, pharmaceuticals containing the same, their use in diagnosis and therapy and process for preparing said complexes and pharmaceuticals | |
DE3633243A1 (en) | Phosphonate complexes | |
EP0540975B1 (en) | Diethylenetriamine derivatives and their use for diagnostic and therapeutic purposes | |
DE19641197C2 (en) | Ion pairs and their use as contrast agents | |
WO1992004056A1 (en) | USE OF RADIOACTIVE METAL ION COMPLEXES WITH all-cis-1,3,5-TRIAMINO-2,4,6-CYCLOHEXANTRIOL AND THEIR DERIVATES FOR X-RAY DIAGNOSIS AND IN TUMOR THERAPY AS WELL AS FOR PRODUCING X-RAY DIAGNOSTIC AND TUMOR THERAPY AGENTS | |
DE4403039A1 (en) | Octaaza macrocycles, their metal complexes, processes for their preparation, agents containing these complexes and their use in diagnostics and therapy | |
AU783982B2 (en) | Calcium complex of phosphorus containing ethylenediamine derivatives | |
DE3151686A1 (en) | "SUBSTITUTED IMINO ACID ACIDS" | |
DE19546234C1 (en) | New macrobicyclic compounds, processes for their preparation and pharmaceutical compositions containing these macrobicyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8130 | Withdrawal |